Comparison of the Magnesium Alterations after Erythropoietin and U-74389G Process

C. Tsompos1, C. Panoulis2, K Toutouzas3, A. Triantafyllou4, C. G Zografos5, K. Tsarea5, M. Karamperi7, A. Papalois8

1ConstantinosTsompos: Department of Gynecology, Anticancer Hospital of Thessaloniki "Theageneio" Thessaloniki, Hellas
2ConstantinosPanoulis: Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Athens, Attiki, Hellas
3Konstantinos Toutouzas: Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Hellas
4AggelikiTriantafyllou: Department of Biologic Chemistry, Athens University, Athens, Attiki, Hellas
5C. G Zografos: Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Hellas
6KalliopiTsarea: Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Pikermi, Attiki, Hellas
7Maria Karamperi: Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Pikermi, Attiki, Hellas
8Apostolos Papalois: Experimental, Educational and Research Center ELPEN European University Cyprus, School of Medicine

*Corresponding Author: TsomposConstantinos, Department of Gynecology Anticancer Hospital of Thessaloniki "Theageneio" AlexandrouSymeonidi street, Thessaloniki Hellas.

Abstract

Aim: This study calculated the effects on serum magnesium (Mg) levels, after treatment with either of 2 drugs: the erythropoietin (Epo) and the antioxidant lazaroide (L) drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the certain influence, after the respective drug usage in an induced ischemia reperfusion (IR) animal experiment.

Materials and methods: The 2 main experimental endpoints at which the serum Mg levels were evaluated was the 60th reperfusion min (for the groups A, C and E) and the 120th reperfusion min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after the L administration.

Results: The first preliminary study of Epo presented a non significant hypomagnesiemic effect by 0.19%±0.10% (p-value=0.9197). However, the second preliminary study of U-74389G presented a significan hypermagnesiemic effect by 0.36%±1.66% (p-value=0.8228). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that L is 1.823808-fold more hypermagnesiemic than Epo (p-value=0.0000).

Conclusion: The anti-oxidant capacities of U-74389G ascribe1.823808-fold more hypermagnesiemic effects than Epo (p-value=0.0000).

Keywords: ischemia; erythropoietin; U-74389G; serum magnesium levels; reperfusion

1. INTRODUCTION

The lazaroide U-74389G (L) may be not famous for its hypermagnesiemic capacity (p-value=0.8228). U-74389G as a novel antioxidant factor, implicates exactly only 261 published studies. The ischemia reperfusion (IR) type of experiments was noted in 19.15% of these studies. A tissue protective feature of U-74389G was obvious in these IR studies. The U-74389G chemically known as 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione maleate salt is an antioxidant complex, which prevents the lipid peroxidation either iron-dependent, or arachidonic acid-induced one. Animal kidney, liver, brain microvascular endothelial cells monolayers and heart models were protected by U-74389G after IR injury. U-74389G also attenuates the leukocytes; down-
regulates the proinflammatory gene; treats the endotoxin shock; produces cytokine; enhances the mononuclear immunity; protects the endothelium and presents antishock property.

Erythropoietin (Epo) even if is not famous for its hypomagnesiemic action (p-value=0.9197), it can be used as a reference drug for comparison with U-74389G. Although Epo is met in over 31,312 published biomedical studies, only a 3.68% of them negotiate the known type of IR experiments. Nevertheless, Epo as a cytokine, it is worth of being studied about its effects on serum magnesium (Mg) levels too. This experimental work tried to compare the effects of the above drugs on a rat induced IR protocol. They were tested by calculating the serumMg levels alterations.

2. MATERIALS AND METHODS

2.1. ANIMAL PREPARATION

The Vet licenses under 3693/12-11-2010 & 14/10-1-2012 numbers, the granting company and the experiment location are mentioned in preliminary references. The human animal care of Albino female Wistar rats, the 7 days pre-experimental ad libitum diet, the non-stop intra-experimental anesthesiologic techniques, the acidometry, the electrocardiogram, the oxygen supply and post-experimental euthanasia are also described in preliminary references. Rats were 16 – 18 weeks old. They were randomly assigned to six (6) groups consisted in N=10. The stage of 45 min hypoxia was common for all 6 groups. Afterwards, reperfusion of 60 min was followed in group A; reperfusion of 120 min in group B; immediate Epo intravenous (IV) administration and reperfusion of 60 min in group C; immediate Epo IV administration and reperfusion of 120 min in group D; immediate U-74389G IV administration and reperfusion of 60 min in group E; and immediate U-74389G IV administration and reperfusion of 120 min in group F. The dose height assessment for both drugs are described at preliminary studies as 10 mg/Kg body mass.

Ischemia was caused by laparotomic clamping the inferior aorta over renal arteries with forceps for 45 min. The clamp removal was restoring the inferior aorta patency and reperfusion. After exclusion of the blood flow, the protocol of IR was applied, as described above for each experimental group. The drugs were administered at the time of reperfusion; through inferior vena cava catheter. The Mg levels were determined at 60th min of reperfusion (for A, C and E groups) and at 120th min of reperfusion (for B, D and F groups). Along, non-relation was raised between Mg values with animals’ mass (p-value=0.9551).

3. STATISTICAL ANALYSIS

Table 1 presents the (%) hypomagnesiemic influence of Epo regarding reoxygenation time. Also, Table 2 presents the (%) hypermagnesiemic influence of U-74389G regarding reperfusion time. Chi-square tests were applied using the ratios which produced the (%) results per endpoint. The outcomes of chi-square tests are depicted at Table 3.

| Table1. The (%) hypomagnesiaim influence of erythropoietin in connection with reperfusion time |
|---------------------------------------------------------------|
| Hypomagnesiemia+SD | Reperfusion time | p-value |
| +1.00% +16.80% | 1h | 0.8596 |
| -1.09% +13.06% | 1.5h | 0.7248 |
| -3.19% +10.32% | 2h | 0.3729 |
| +4.22% +13.14% | reperfusion | 0.1794 |
| -0.19% +0.10% | interaction | 0.9197 |

| Table2. The (%) hypermagnesiaim influence of U-74389G in connection with reperfusion time |
|---------------------------------------------------------------|
| Hypomagnesiemia+SD | Reperfusion time | p-value |
| +1.33% +11.02% | 1h | 0.7033 |
| -0.28% +12.36% | 1.5h | 0.9171 |
| -1.90% +16.81% | 2h | 0.7161 |
| +4.28% +11.40% | reperfusion | 0.1074 |
| +0.36% +1.66% | interaction | 0.8228 |

| Table3: The U-74389G / erythropoietin magnesium alterations efficacies after chi-square tests application |
|---------------------------------------------------------------|
| Odds ratio | [95% Conf. Interval] | p-values | Endpoint |
| 1.331108 | 1.324786 | 1.33746 | 0.0000 | 1h |
| 0.2605466 | .2587177 | .2623884 | 0.0000 | 1.5h |
Comparison of the Magnesium Alterations after Erythropoietin and U-74389G Process

| 0.5961915 | 0.5942638 | 0.5981254 | 0.00000 | 2h          |
|-----------|-----------|-----------|----------|-------------|
| 1.013227  | 1.010824  | 1.015635  | 0.0000   | reperfusion |
| 1.823808  | 1.806514  | 1.841268  | 0.0000   | interaction |

4. RESULTS

The successive application of chi-square tests revealed that U-74389G caused hypermagnesiemicby1.331108-fold [1.324786 - 1.33746] more than Epo at 1h (p-value=0.00007), by 0.2605466-fold [0.2587177 - 0.2623884] less hypomagnesiemicthan Epo at 1.5h (p-value=0.0000), by 0.5961915-fold [0.5942638 - 0.5981254] less hypomagnesiemicthan Epo at 2h (p-value=0.0000), by 1.013227-fold [1.010824 - 1.015635] more hypermagnesiemic(p-value=0.0000) without drugs andby1.823808-fold [1.806514 - 1.841268] morehypermagnesiemicthan Epo whether all variables have been considered (p-value=0.0000).

5. DISCUSSION

The unique available study investigating thehypermagnesiemic effect of U-74389G was the preliminary one. Although the most famous activities of neuroprotection and membrane-stabilization properties, it accumulates in the cell membrane, protecting vascular endothelium from peroxidative damage but hardly penetrates the blood-brain barrier. It elicits a beneficial effect in otoxicity and Duchenne muscular dystrophy. It increases γgt, superoxide dismutase (SOD) and glutathione (GSH) levels in oxygen-exposed cells. It treats septic states and acts as immunosuppressant in flap survival. It prevents the learning impairments, it delays the early synaptic transmission decay during hypoxia improving energetic state of neurons. It shows antiproliferative properties on brain cancer cells and is considered as a new promising anti inflammatory drug for the treatment of reperfusion syndrome in IR injuries.

The same authors confirmed 2 the short-termhypomagnesiemic effect of Epo preparations in non iron deficient individuals. Lee MY et al determined 3 changes in blood Mg2+ and tMg after hemorrhage identifying mechanism and origin of the changes in blood Mg2+. Hemorrhagic shock produced significant increases in blood Mg2+, but significant decreases in RBC tMg. During hemorrhagic shock, K+, anion gap, and BUN showed significant positive correlations with changes in blood Mg2+ level, while Ca2+, pH, and T-CHO were correlated with Mg2+ in a negative manner. Thus, hemorrhagic shock induced an increase in both blood-free Mg2+ and tMg, resulting from Mg2+ efflux from metabolic damaged cell with acidosis and ATP depletion in rats. Wang AF et al found 4 potassium, calcium, magnesium and to some extent, boron and zinc concentrations decreased in both Betula species and additionally manganese in B. pendula likely connected with impaired root functioning, which was not yet fully recovered from GW. Chubanov V et al uncovered 5 new cellular functions of the transient receptor potential cation channel subfamily M member 7 (TRPM7) in situ including its crucial role in Ca2+ signaling and Ca2+-dependent cellular processes. Genetic inactivation of this bi-functional protein revealed its crucial role in Ca2+ signalling, Mg2+ metabolism, immune responses, cell motility, proliferation and differentiation. Reilly-O’Donnell B et al suggested 6 that dysregulated Zn2+ homeostasis alters the function of both RyR2 and MG23 and that both ion channels play a key role in diastolic SR Ca2+ leakage in H9C2 cells exposed to ischemic conditions. Koning G et al noticed 7 that mRNAs/miRNAs is involved in mitochondrial function and metabolism were modulated by MgSO4. Metabolomic analysis (H+ NMR) disclosed that MgSO4 attenuated hypoxia-ischemia (HI)-induced increases in succinate and prevented depletion of high-energy phosphates. MgSO4 pretreatment preserved mitochondrial respiration, reducing ROS production and inflammation after HI. Therefore, we propose that MgSO4 evokes preconditioning via induction of mitochondrial resistance and attenuation of inflammation in seven-day-old rats. Poore LA et al diagnosed 8 urolithiasis, with uroliths identified as magnesium calcium phosphate carbonate in composition in a hand-reared 5-month-old steenbok. Groom KM et al used 9 of peripartum maternal administration of magnesium sulphate for neuroprotection and corticosteroids for fetal lung maturity, to prevent adverse neonatal outcomes. Wolff A et al included 10 the delta opioid receptor agonist D-Ala-Leu-enkephalin (DADLE), the gasotransmitter hydrogen sulfide, combinations of adenosine, lidocaine, and magnesium (ALM) or D-beta-hydroxybutyrate and melatonin (BHB/M) and therapeutic hypothermia in hibernation as a treatment of hemorrhagic shock. Koning G et al resulted 11 in a transient serum Mg2+ concentration elevation at 3 h post i.p. injection), reduced brain injury by 74% in grey matter and 64% in white matter after MgSO4 administration i.p. 24 h prior to the induction of HI. MgSO4
provides a marked preconditioning protection both in postnatal day 4 and in postnatal day 5 in mice. Seyama T et al attenuated⁵ the loss of premyelinating oligodendrocytes (pre-OL) markers, such as myelin basic protein and Olig2, in ipsilateral pericellosal white matter and decreased the number of CD-68-positive microglia and TUNEL-positive cells in vivo; also inhibited lactate dehydrogenase release from pre-OL induced by oxygen glucose deprivation in vitro after antenatal maternal pretreatment with MgSO₄ in a neonatal rat model. Mu YP et al found¹³ that increasing the magnesium concentration attenuates vasoconstriction and improves vasodilatation via release of nitric oxide. Pulmonary hypertension is associated with endothelial dysfunction resulting in the suppression of magnesium modulation of vasodilatation. Magnesium regulates vascular functions by altering the vascular responses to vasodilator and vasoactive agonists and affects endothelial function by modulating endothelium-dependent vasodilatation in hypertension. Removal of extracellular magnesium suppressed vasoreactivity of pulmonary hypertension (PA)s. A high concentration of magnesium (4.8 mm) inhibited ET-1-induced vasconstriction in endothelium-intact or endothelium-disrupted pulmonary arterial (PA)s of normoxic and chronic hypoxia (CH)-treated mice, and enhanced the ACh-induced production of NO in PAs of normoxic mice. Moreover, magnesium enhanced ACh-induced vasodilatation in PA:s of normoxic mice. Hence, in this study we demonstrated that increasing the magnesium concentration can attenuate the ET-1-induced contractile response. Bennet L et al affirmed that MgSO₄ significantly reduced¹⁴ the total duration, number of seizures, seizure amplitude, average seizure burden, the total number of seizures (P < 0.001), peak seizure amplitude (P < 0.05) and seizure burden (P < 0.005) after hypoxia-ischaemia. Finally, seizures showed a circadian profile with peak seizures between 04.00 and 06.00 h on the first and second day post-UCO. Collectively, these results suggest that MgSO₄ may have utility in treating perinatal seizures and has sexually dimorphic effects in preterm fetal sheep. Chollat C et al decreased the induced lesions' sizes and inflammatory cytokine levels, prevented cell death, and improved long-term behavior and reduced risks of cerebral palsy after antenatal magnesium sulfate preconditioning therapy in hypoxia models, including¹⁵ hypoxia-ischemia, inflammation, and excitotoxicity in various species (mice, rats, pigs). Dhillon SK et al gave¹⁶ treatments such as antenatal glucocorticoids and magnesium sulphate to reduce the risk of death and complications after preterm birth in mothers who are at risk of premature delivery and have high rates of diabetes and antepartum infection/inflammation. Samsonia M et al have shown¹⁷ factors such as - enhancement of the antioxidant systems of neurons by acetylcysteine, inhibition of glutamate excitotoxicity by lamotrigine and correction of ion stress by magnesium ions, critically increase the time prior to apnea. Accordingly, the combination of magnesium sulfate, lamotrigine and acetylcysteine is able to protect brain cells from the damaging effects of oxygen-glucose deprivation and can be effectively used for pharmacological correction of hypoxic brain damage in acute ischemic stroke. Meloni BP et al indicated¹⁸ that magnesium is only neuroprotective when combined with post-ischemic hypothermia in cerebral ischemia models. Ogunyemi D et al associated untreated anxiety/depression with magnesium exposure (aOR = 1.82) for independent maternal outcomes in subjects¹⁹ more likely being Non-Hispanic Whites, using tobacco, public insurance and illegal substances, unmarried, and having medical complications of pregnancy. Kumar V et al found calcium, magnesium, and phosphorous amounts decreased but the strongest decline was seen²⁰ for potassium, whereas, photosynthesis-related parameters were hardly affected, thus accumulated carbohydrates under all stresses and anthocyanins under Hpx exclude carbohydrate limitation in rosettes. Daher I et al noted that MgSO₄ prevented²¹ sensorimotor alterations in pups, with the same efficacy in males and females, displayed anti-apoptotic and anti-inflammatory effects without deleterious side effects, tended to prevent these motor and cognitive deficits only in females, while it prevented global brain tissue damage in both sexes. Liu Y et al²² directly removed the intratumoral oxygen via the oxidation reactions of Mg₃Si nanoparticles and later efficiently block the rapid reoxygenation via tumor blood vessels by the resultant SiO₂-microsheets for cancer starvation therapy. Chollat C et al found the resulting lesion sizes and inflammatory cytokine levels decreased²³, prevented cell death, and improved long-term cognitive and motor behaviours in models of hypoxia, hypoxia-ischemia, inflammation, and excitotoxicity after magnesium sulphate preconditioning in various animal species. However, antenatal magnesium sulphate as a neuroprotectant showed prevention of CP at 2 years in infants born preterm when administered to females at risk of imminent preterm birth in humans. Plush K et al tended²⁴ to find reduced the negative impacts of birth hypoxia, higher vitality scores immediately after birth (p <
Comparison of the Magnesium Alterations after Erythropoietin and U-74389G Process

0.10), quicker to colostrum suck and higher day one blood glucose concentrations in Mg piglets than Cont piglets (p < 0.05) during the peri-natal period. Dumanska H et al observed hypoxia-induced reduction of voltage-dependent magnesium blockade of evoked N-methyl-D-aspartate receptor (NMDA) response in retinocollicular synaptic transmission. Bagheri G et al revealed that MS reduced the number and intensity of necrotic insults. The Bax/Bcl2 ratio and malondialdehyde (MDA) levels were significantly decreased in a dose-dependent manner in the MS-treated rats compared with the positive control group, while a significant dose-dependent increase in Akt expression, a pro-survival protein, was observed. In addition, MS administration reduced pro-apoptotic indice levels, ameliorated histological insults, favorably modulated oxidative status and increased Akt expression levels, indicating a possible neuroprotective effect in the case of CO poisoning resulting in protecting against CO-induced cerebral injury in male Wistar rats. Lisukha LM et al determined the content of magnesium (Mg2+) electrolytes having a multidirectional signiﬁcance in different age groups in non-stimulated mixed saliva of children, with disorders of autonomous nervous system (ANS), who were born and are permanently residing at radioactive contaminated territories after application of intermittent normo-baric hypoxia (INH) of sanogenic level. Adam GO et al revealed that the levels of magnesium (Mg2+), and calcium (Ca2+) were signiﬁcantly decreased whereas Ca2+/Mg2+ were signiﬁcantly increased than those found pre toxemia induction in acute lipopolysaccharide (LPS)-toxemia models. Li T et al showed that MLB prevented the elevation in right ventricular systolic pressure and the increase in ratio of wall thickness to vessel external diameter of pulmonary arteries in PAH rats, attenuated phenotypic transformation of PASMCs (decrease in α-smooth muscle actin while increase in osteopontin), accompanied by downregulation of NADPH oxidase (NOX) (NOX2 and NOX4) protein levels, decrease of ROS and H2O2 production, and suppression of the phosphorylation of ERK. Pradhan T et al signiﬁcantly related the mortality with the number of seizure episodes and time interval between seizure onset and administration of magnesium sulphate. Early detection of hypertension and management with magnesium sulphate for eclampsia can help to minimize the maternal and fetal adverse outcomes in patients with eclampsia. Lin P et al noticed that magnesiumlithospermate B (MLB) can promote renal microcirculation, improves renal function, ﬁbrosis and inﬂammation and signiﬁcantly reduces 24hUp, Scr, BUN, SBP and DBP levels. The expression of FN, Col-I, CTGF and IL-6 were down-regulated by MLB treatment whereas signiﬁcantly increased RBF. MLB reversed the expression of nNOS (neuronal nitric oxide synthase), HIF-1α (hypoxia inducible factor-1) and VEGF in rats with CRF in the remnant kidney with CRF. Xu L et al measured increased proliferation with Mg extracts under hypoxia but not under normoxia. Under normoxia and with Mg extracts, HUVEC migration exhibited a bell-shaped curve. Under normoxia and increased Mg concentrations, a general negative effect was measured on early (migration) and late (tubulogenesis) angiogenesis; as magnesium degradation is an oxygen-dependant process in vitro in human primary endothelial cells. Li T et al showed hypertrophic features (increases in the ratio of RV weight to tibia length, cellular size, and hypertrophic marker expression), accompanied by upregulation in expression of NADPH oxidases (NOX2 and NOX4) and vascular peroxidase 1 (VPO1), increases in hydrogen peroxide (H2O2) and hypochlorous acid (HOCl) production and elevation in phosphorylation levels of ERK; attenuated by treating rats with Magnesium lithospermate B (MLB) in hypoxic pulmonary arterial hypertension (PAH) SD rats. Solevág AL et al targeted the acute brain injury in neonatal asphyxia phase after allopurinol, melatonin, noble gases such as xenon and argon, and magnesium administration also. Xing J et al reported the transient receptor potential melastatin 7 (TRPM7) as an endogenous magnesium channel to promote the proliferation of SMCs. The TRPM7 currents and intracellular magnesium level in PASMCs were also reduced by pulmonary arterial hypertension (PAH) stimuli. Functionally, TRPM7 inhibition with wxainecin A or knockdown promoted and reversely, its overexpression inhibited the proliferation and apoptosis resistance of PASMCs in Sprague-Dawley rats. Lingam I et al noticed that MgSO4 bolus and infusion doubled serum magnesium (0.72 vs 1.52 mmol/L) with modest (16%) rise in CSF. In Mg+HT compared with HT, there was overall reduced cell death (p = 0.01) and increased oligodendrocytes (p = 0.002) in a piglet model of term neonatal encephalopathy. Wagner S et al generated an integrated picture of the physiological response to progressing hypoxia monitoring cytosolic dynamics of magnesium adenosine 5′-triphosphate, free calcium ion concentration, pH, NAD redox status, and glutathione redox status in parallel, linked to transcriptional and metabolic responses. Mi F et al observed that Mg2+ protected...
Comparison of the Magnesium Alterations after Erythropoietin and U-74389G Process

HT22 cells against hypoxia-induced damages by upregulating microRNA-221 (miR-221) and NGF in mouse hippocampal HT22 cells. El Farargy MS et al assessed that MgSO4 may have an added effect for the reduction in brain injury through the expression of S100-B, a marker of brain injury, in neonates infants with HIE who are receiving melatonin. Xu L et al noticed that Mg degradation products increased human umbilical cord perivascular (HUCPV) migration, remarkably increased cytokines (e.g., c-c motif chemokine ligand 2 and vascular endothelial growth factor) and MSC mineralization, decreased and increased the mesenchymal stem cells (MSC) proliferation in transwell and in heterotypic-contact coculture, respectively in transfswell under hypoxia.

According to above, table 3 shows that U-74389G has 1.823808-fold [1.806514 - 1.841268] more hypermagnesemian than Epo whether all variables have been considered (p-value=0.0000); a trend attenuated along time, in Epo non-deficient rats. A meta-analysis of these ratios from the same experiment, for 29 other seric variables, provides comparable results (table 4).

Table 4. A U-74389G / erythropoietin efficacies ratios meta-analysis on 29 hematologic variables.

| Endpoint Variable | 1h p-value | L5h p-value | 2h p-value | Reperfusion time p-value | Interaction p-value |
|-------------------|------------|-------------|------------|--------------------------|---------------------|
| WBC                | 0.957451   | 0.3782      | 1.396122   | 0.0000                   | 1.918237            |
| RBC (bill)         | 0.961059   | 0.0000      | 1.733395   | 0.0000                   | 6.519657            |
| Hematocrit (%)     | 38.424     | 0.0000      | 9.076658   | 0.0000                   | 6.222898            |
| Hemoglobin (g/dL)  | 1.268869   | 0.0000      | 1.839035   | 0.0000                   | 13.1658             |
| MCH                | 151.125    | 0.0000      | 4.246814   | 0.0000                   | 2.749729            |
| MCV                | 120.8581   | 0.0000      | 4.236722   | 0.0000                   | 2.704247            |
| MCHC               | 3.6046103  | 0.0000      | 1.816622   | 0.0000                   | 1.173373            |
| RBcDW              | 3.306773   | 0.0000      | 3.023389   | 0.0000                   | 6.265885            |
| Platelet count     | 2.42839    | 0.0000      | 0.00238    | 0.0000                   | 6.133342            |
| MPV                | 145.8532   | 0.0000      | 0.003516   | 0.0000                   | 2.603947            |
| Platelet DW        | 0.6940233  | 0.0000      | 1.319118   | 0.0000                   | 2.206972            |
| Platelets          | 4.3251772  | 0.0000      | 1.488235   | 0.0000                   | 0.751452            |
| Glucose            | 156.4991   | 0.0000      | 4.53659    | 0.0000                   | 2.81397            |
| Urea               | 158.4209   | 0.0000      | 4.50889    | 0.0000                   | 2.850291            |
| Creatinemia        | 168.9034   | 0.0000      | 4.357322   | 0.0000                   | 3.039572            |
| Total proteins     | 155.9562   | 0.0000      | 4.421079   | 0.0000                   | 2.803573            |
| Albumin            | 0.2457507  | 0.0073      | 0.530347   | 0.0000                   | 0.624305            |
| ALT                | 0.5955473  | 0.0000      | 0.86405406 | 0.0000                   | 7.967324            |
| AST                | 1.149266   | 0.0391      | 0.9347365  | 0.0000                   | 0.669575            |
| γGT                | 1          | 1.0000      | 0.5367033  | 0.0000                   | 1.0606061           |
| ALP                | 134.0033   | 0.0000      | 3.602703   | 0.0000                   | 2.349961            |
| ACP                | 2.774031   | 0.0000      | 5.450674   | 0.0000                   | 7.86942             |
| CPK                | 144.0769   | 0.0000      | 3.987264   | 0.0000                   | 2.567192            |
| CK-MB               | 141.313    | 0.0000      | 3.883186   | 0.0000                   | 2.509108            |
| LDH                | 142.9228   | 0.0000      | 3.944068   | 0.0000                   | 2.543149            |
| Sodium             | 1.695709   | 0.0000      | 0.8085706  | 0.0000                   | 3.088772            |
| Potassium (mm)     | 1.646018   | 0.0000      | 0.968488   | 0.0000                   | 3.346145            |
| Chlode             | 0.5544784  | 0.0007      | 0.8643683  | 0.0000                   | 1.07745             |
| Calcium            | 0.0000033  | 0.0000      | 0.249068   | 0.0000                   | 0.198875            |
| Mean               | 5.6905513  | 0.0490      | 2.141617   | 0.0000                   | 2.393135            |

6. Conclusion

The anti-oxidant agent U-74389G was proved having 1.823808-fold [1.806514 - 1.841268] more hypermagnesemic effect than Epo whether all variables have been considered (p-value=0.0000); a trend attenuated along the short term time frame of the experiment in rats. A biochemical investigation remains about how U-74389G mediates in these actions.
Comparison of the Magnesium Alterations after Erythropoietin and U-74389G Process

REFERENCES

[1] Tsompos C, Panoulis C, Toutouzas K, Zografos G, Papalois A. The Effect of the Antioxidant Drug U-74389G on Magnesium Levels During Hypoxia–Reoxygenation Injury in Rats. Annals of the Russian Academy of Medical Sciences. 2015; 70 (4): 408–412.

[2] Tsompos C, Panoulis C, Toutouzas K, Zografos G, Papalois A. The effect of erythropoietin on magnesium during ischemia reperfusion injury in rats. Revista Romana de Neurologie 2014;13(1):17-22.

[3] Lee MY, Yang DK, Kim SJ. Alterations of Mg\(^{2+}\) After Hemorrhagic Shock. Biol Trace Elem Res. 2017 Nov;180(1):120-126.

[4] Wang AF, Roitto M, Lehto T, Sutinen S, Heinonen J, Zhang G, Repo T. Photosynthesis, nutrient accumulation and growth of two Betula species exposed to waterlogging in late dormancy and in the early growing season. Tree Physiol. 2017 Jun 1;37(6):767-778.

[5] Chubanov V, Fериоли S, Gudermann T. Assessment of TRPM7 functions by drug-like small molecules. Cell Calcium. 2017 Nov;67:166-173.

[6] Reilly-O’Donnell B, Robertson GB, Karumbi A, McIntyre C, Bal W, Nishi M, Takeshima H, Stewart AJ, Pitt SJ. Dysregulated Zn\(^{2+}\) homeostasis impairs cardiac type-2 ryanodine receptor and mitsugumin 23 functions, leading to sarcoplasmic reticulum Ca\(^{2+}\) leakage. J Biol Chem. 2017 Aug 11;292(32):13361-13373.

[7] Koning G, Leverin AL, Nair S, Schwendimann L, Ek J, Carlsson Y, Gressens P, Thornton C, Wang X, Mallard C, Hagberg H. Magnesium induces preconditioning of the neonatal brain via profound mitochondrial protection. J Cereb Blood Flow Metab. 2019 Jun;39(6):1038-1055.

[8] Poore LA, Hendry R, Steyl J, Pfitzer S. Perineal urethrostomy to treat obstructive urolithiasis in a captive hand-raised steenbok (<i>Raphicerus campestris</i>). J S Afr Vet Assoc. 2017 Dec 8;88(4):e1-e6.

[9] Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018 Feb;218(2S):S829-S840.

[10] Wolf A, Luszczek ER, Beilman GJ. Hibernation-Based Approaches in the Treatment of Hemorrhagic Shock. Shock. 2018 Jul;50(1):14-23.

[11] Koning G, Lyngefelt E, Svedin P, Leverin AL, Jinnai M, Gressens P, Thornton C, Wang X, Mallard C, Hagberg H. Magnesium sulphate induces preconditioning in preterm rodent models of cerebral hypoxia-ischemia. Int J Dev Neurosci. 2018 Nov;70:56-66.

[12] Seyama T, Kamei Y, Iriyama T, Imada S, Ichinose M, Toshimitsu M, Fujii T, Asou H. Pretreatment with magnesium sulfate attenuates white matter damage by preventing cell death of developing oligodendrocytes. J Obstet Gynaecol Res. 2018 Apr;44(4):601-607.

[13] Mu YP, Huang QH, Zhu IL, Zheng SY, Yan FR, Zhuang XL, Sham JSK, Lin MJ. Magnesium attenuates endothelin-1-induced vasoreactivity and enhances vasodilatation in mouse pulmonary arteries: Modulation by chronic hypoxic pulmonary hypertension. Exp Physiol. 2018 Apr 1;103(4):604-616.

[14] Bennet L, Galinsky R, Draghi V, Lear CA, Davidson JO, Unsworth CP, Gunn AJ. Time and sex dependent effects of magnesium sulphate on post-asphyxial seizures in preterm fetal sheep. J Physiol. 2018 Dec;596(23):6079-6092.

[15] Chollat C, Sentilhes L, Marret S. Fetal Neuroprotection by Magnesium Sulfate: From Translational Research to Clinical Application. Front Neurol. 2018 Apr 16;9:247.

[16] Dhillon SK, Lear CA, Galinsky R, Wassink G, Davidson JO, Juul S, Robertson NJ, Gunn AJ, Bennet L. The fetus at the tipping point: modifying the outcome of fetal asphyxia. J Physiol. 2018 Dec;596(23):5571-5592.

[17] Samsonia M, Kandelaki M, Baratashvili N. EVALUATION OF NEUROPROTECTIVE ACTIVITY OF COMPLEX IMPACT OF MAGNESIUM OF SULFATE, LAMOTRYGINE AND N-ACETYLCYSTEINE UNDER CONDITIONS OF COMBINED NORMOBARIC HYPOXIA WITH LIGATION OF RIGHT CAROTID ARTERY IN RATS. Georgian Med News. 2018 May;(278):172-177.

[18] Meloni BP, Campbell K, Knuckey NW. The use of magnesium in experimental cerebral ischemia. Magnesium in the Central Nervous System [Internet]. Adelaide (AU): University of Adelaide Press; 2011.

[19] Ogunyemi D, Jovanovski A, Liu J, Friedman P, Sugiyama N, Creps J, Madan I. The Contribution of Untreated and Treated Anxiety and Depression to Prenatal, Intrapartum, and Neonatal Outcomes. AJP Rep. 2018 Jul;8(3):e146-e157.

[20] Kumar V, Vogelsang L, Seidel T, Schmidt R, Weber M, Reichelt M, Meyer A, Clemens S, Sharma SS, Dietz KJ. Interference between arsenic-induced toxicity and hypoxia. Plant Cell Environ. 2019 Feb;42(2):574-590.
Comparison of the Magnesium Alterations after Erythropoietin and U-74389G Process

[21] Daher I, Le Dieu-Lugon B, Lecointre M, Dupré N, Voisin C, Leroux P, Dourmap N, Gonzalez BJ, Marret S, Leroux-Niclot I, Cleren C. Time- and sex-dependent efficacy of magnesium sulfate to prevent behavioral impairments and cerebral damage in a mouse model of cerebral palsy. Neurobiol Dis. 2018 Dec;120:151-164.

[22] Liu Y, Jiang Y, Zhang M, Tang Z, He M, Bu W. Modulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors. Acc Chem Res. 2018 Oct 16;51(10):2502-2511.

[23] Chollat C, Sentilhes L, Marret S. Protection of brain development by antenatal magnesium sulphate for infants born preterm. Dev Med Child Neurol. 2019 Jan;61(1):25-30.

[24] Plush K, Weaver A, Staveley L, van Wettere W. Maternal Magnesium Sulfate Supplementation in a Pre-Farrow Diet Improves Factors Important for Piglet Viability. Animals (Basel). 2018 Oct 22;8(10). pii: E185.

[25] Dumanska H, Veselovsky N. Short-term hypoxia induces bidirectional pathological long-term plasticity of neurotransmission in visual retinocollicular pathway. Exp Eye Res. 2019 Feb;179:25-31.

[26] Bagheri G, Rezaee R, Tsarouhas K, Docea AO, Shahraki J, Shahriari M, Wilks MF, Jahantigh H, Tabrizian K, Moghadam AA, Bagheri S, Spandidos DA, Tsatsakis A, Hashemzaei M. Magnesium sulfate ameliorates carbon monoxide-induced cerebral injury in male rats. Mol Med Rep. 2019 Feb;19(2):1032-1039.

[27] Lisukha LM, Stepanova YI, Kolpakov YI, Podrushnyak AY. ELECTROLYTE CONTENT IN SALIVA OF CHILDREN WITH DEVIAITON IN VEGETATIVE STATUS RESIDING AT RADIOACTIVELY CONTAMINATED TERRITORIES OF UKRAINE AFTER APPLICATION OF INTERMITTENT NORMOBARIC HYPOXIA. Probl Radiac Med Radiobiol. 2018 Dec;23:359-372.

[28] Adam GO, Lee HR, Lee SJ, Kim SJ, Kim GB, Kang HS. Effects of acute lipopolysaccharide-induced toxemia model on some neglected blood parameters. Pol J Vet Sci. 2018 Dec;21(4):665-671.

[29] Li T, Luo XJ, Wang EL, Li NS, Zhang XJ, Song FL, Yang JF, Liu B, Peng J. Magnesium lithospermate B prevents phenotypic transformation of pulmonary arteries in rats with hypoxic pulmonary hypertension through suppression of NAPDH oxidase. Eur J Pharmacol. 2019 Mar 15;847:32-41.

[30] Pradhan T, Rijal P, Rai R, Bhatta RD, Thapa BD, Regmi MC. Adverse Maternal and Fetal Outcome in Patients with Eclampsia. J Nepal Health Res Coun. 2019 Jan 28;16(41):425-427.

[31] Lin P, Wu M, Qin J, Yang J, Ye C, Wang C. Magnesium lithospermate B improves renal hemodynamics and reduces renal oxygen consumption in 5/6th renal ablation/infarction rats. BMC Nephrol. 2019 Feb 12;20(1):49.

[32] Xu L, Willumeit-Römer R, Luthringer-Feyerabend BJ. Effect of magnesium-degradation products and hypoxia on the angiogenesis of human umbilical vein endothelial cells. Acta Biomater. 2019 Oct 15;98:269-283.

[33] Li T, Peng JJ, Wang EL, Li NS, Song FL, Yang JF, Luo XJ, Liu B, Peng J. Magnesium Lithospermate B Derived from Salvia miltiorrhiza Ameliorates Right Ventricle Remodeling in Pulmonary Hypertensive Rats via Inhibition of NOX/VPO1 Pathway. Planta Med. 2019 Jul;85(9-10):708-718.

[34] Solevág AL, Schmöller GM, Cheung PY. Novel interventions to reduce oxidative-stress related brain injury in neonatal asphyxia. Free Radic Biol Med. 2019 Oct;142:113-122.

[35] Xing J, Wang M, Hong J, Gao Y, Liu Y, Gu H, Dong J, Li L. TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway. Aging (Albany NY). 2019 Jun 19;11(12):4050-4065.

[36] Lingam I, Meehan C, Avdic-Belltheus A, Martinello K, Hristova M, Kaynezhad P, Bauer C, Tachtsidis I, Golay X, Robertson NJ. Short-term effects of early initiation of magnesium infusion combined with cooling after hypoxia-ischemia in term piglets. Pediatr Res. 2019 Jul 29.

[37] Wagner S, Steinbeck J, Fuchs P, Lichtenauser S, Elsässer M, Schippers JHM, Nietzel T, Ruberti C, Van Aken O, Meyer AJ, Van Dongen JT, Schmidt RR, Schwarzlander M. Multiparametric real-time sensing of cytosolic physiology links hypoxia responses to mitochondrial electron transport. New Phytol. 2019 Dec;224(4):1668-1684.

[38] Mi F, Liu F, Zhang C. Magnesium protects mouse hippocampal HT22 cells against hypoxia-induced injury by upregulation of miR-221. J Cell Biochem. 2019 Sep 12.

[39] El Farargy MS, Soliman NA. A randomized controlled trial on the use of magnesium sulfate and melatonin in neonatal hypoxic ischemic encephalopathy. J Neonatal Perinatal Med. 2019 Sep 8.

[40] Xu L, Willumeit-Römer R, Luthringer-Feyerabend B. Hypoxia influences the effects of magnesium degradation products on the interactions between endothelial and mesenchymal stem cells. Acta Biomater. 2019 Oct 14. pii: S1742-7061(19)30694-4.

International Journal of Research Studies in Microbiology and Biotechnology (IJRSMB)
[41] Tsompos C, Panoulis C, Toutouzas K, Triantafyllou A, Zografos G C, Tsarea K, Karamperi M, Papalois A. Comparison of the Hypochloremic Effects of Erythropoietin and U-74389G. GMJ Medicine. 2019; 3: 156-163.

[42] Tsompos C, Panoulis C, Toutouzas K, Triantafyllou A, Zografos CG, Tsarea K, Karamperi M, Papalois A. Comparison of the Hypocalcemic Effects of Erythropoietin and U-74389G. Clin Res Hematol 2019;2(2):1-8.

Copyright: © 2019 Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.